Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

SUMMARY: Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase 1 study evaluating the effect of rifampin, a strong...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Vaishampayan, Ulka, Mahalingam, Devalingam, Harvey, R. Donald, Chung, Ki Young, Sedarati, Farhad, Dong, Cassie, Faller, Douglas V., Venkatakrishnan, Karthik, Gupta, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395450/
https://www.ncbi.nlm.nih.gov/pubmed/35932388
http://dx.doi.org/10.1007/s10637-022-01286-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395450/
https://www.ncbi.nlm.nih.gov/pubmed/35932388
http://dx.doi.org/10.1007/s10637-022-01286-8

Ejemplares similares